KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2021 - 2025)

TherapeuticsMD (TXMD) has disclosed Liabilities from Discontinued Operations for 6 consecutive years, with 2667000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities from Discontinued Operations fell 8.79% year-over-year to 2667000.0, compared with a TTM value of 2667000.0 through Sep 2025, down 8.79%, and an annual FY2024 reading of 2781000.0, down 24.72% over the prior year.
  • Liabilities from Discontinued Operations was 2667000.0 for Q3 2025 at TherapeuticsMD, down from 2722000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 47911000.0 in Q4 2021 and bottomed at 2667000.0 in Q3 2025.
  • Average Liabilities from Discontinued Operations over 5 years is 8246600.0, with a median of 3266500.0 recorded in 2024.
  • The sharpest move saw Liabilities from Discontinued Operations crashed 84.62% in 2022, then decreased 8.79% in 2025.
  • Year by year, Liabilities from Discontinued Operations stood at 47911000.0 in 2021, then plummeted by 84.62% to 7369000.0 in 2022, then tumbled by 49.87% to 3694000.0 in 2023, then dropped by 24.72% to 2781000.0 in 2024, then dropped by 4.1% to 2667000.0 in 2025.
  • Business Quant data shows Liabilities from Discontinued Operations for TXMD at 2667000.0 in Q3 2025, 2722000.0 in Q2 2025, and 2785000.0 in Q1 2025.